



SASINI PLC RIVANA CENTRE, OFF WAIYAKI WAY, BROOKSIDE GROOVE, MUGUGA GREEN P.O. BOX 30151-00100, NAIROBI (A Member of The Sameer Group) ANNOUNCEMENT OF RESULTS FOR THE YEAR ENDED 30 SEPTEMBER 2019 (Audited)																				
CONSOLIDATED AND COMPANY STATEMENT OF PROFIT OR LOSS AND COMPREHENSIVE INCOME																				
	Group		Company																	
	30.09.2019 Kes '000	30.09.2018 Kes '000	30.09.2019 Kes '000	30.09.2018 Kes '000																
Revenue	2,794,830	3,512,220	988,016	1,076,088																
(Loss)/gain arising from changes in fair value of biological assets less cost to sell	(5,843)	55,559	(64,596)	34,747																
Results from operations	(392,109)	354,615	(12,858)	422,053																
Finance income	51,736	112,663	26,366	32,067																
Finance cost	(20,926)	(18,472)	(17,366)	(5,143)																
(Loss)/profit before tax	(361,299)	448,806	(3,858)	448,977																
Tax credit / (charge)	23,562	(155,283)	56,620	(31,352)																
(Loss)/profit for the year	(337,737)	293,523	52,762	417,625																
Other Comprehensive Income																				
Revaluation gain net of tax	2,181,675	-	1,529,028	-																
Remeasurement of post employment benefits net of tax	16,202	8,453	465	909																
Total comprehensive income	1,860,140	301,976	1,582,255	418,534																
(Loss)/profit attributable to:																				
Non-controlling interest	(20,308)	(1,974)	-	-																
Owners of the company	(317,429)	295,497	52,762	417,625																
(Loss)/profit arising from operating activities	(317,429)	295,497	52,762	417,625																
(Loss)/gain arising from changes in fair value in biological assets after tax	(314,197)	256,606	97,979	393,302																
(Loss)/gaining per share (Kes ) on operating activities	(3.232)	38.891	(45.217)	34.747																
(Loss)/ earning per share (Kes ) on biological assets	(317,429)	295,497	52,762	417,625																
(Loss)/earning per share (Kes ) on operating activities	(1.38)	1.13	0.43	1.72																
(Loss)/ earning per share (Kes ) on biological assets	(0.01)	0.17	(0.20)	0.11																
(Loss)/ earning per share (Kes )	(1.39)	1.30	0.23	1.83																
Issued and fully paid shares of Kes 1 each	228,055	228,055	228,055	228,055																
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY																				
	Share Capital Kes '000	Capital Reserves Kes '000	Revaluation Reserves Kes '000	Defined Benefit Reserves Kes '000	Biological Assets Fair Value Kes '000	Retained Earnings Kes '000	Proposed Dividends Kes '000	Non Controlling Interest Kes '000	Total Kes '000											
At 1 October 2017	228,055	96,530	7,627,565	26,128	159,711	2,698,759	171,042	306,087	11,315,877											
Profit for the year	-	-	-	-	-	295,497	-	(1,974)	293,523											
Fair value gain on biological assets	-	-	-	-	38,891	(38,891)	-	-	-											
Other comprehensive income	-	-	-	8,443	-	-	-	10	8,453											
Final 2017 dividend paid	-	-	-	-	-	-	(171,042)	-	(171,042)											
First Interim 2018 dividend Paid	-	-	-	-	-	(114,028)	-	-	(114,028)											
Second Interim 2018 dividend payable	-	-	-	-	-	(114,028)	-	-	(114,028)											
At 30 September 2018	228,055	96,530	7,627,565	34,571	198,602	2,727,309	114,028	295,123	11,323,783											
At 1 October 2018 as originally presented	228,055	96,530	7,627,565	34,571	198,602	2,727,309	114,028	295,123	11,323,783											
Change in accounting policy	-	-	-	-	-	(34,880)	-	(682)	(35,562)											
Restated as at 1 October 2018	228,055	96,530	7,627,565	34,571	198,602	2,692,429	114,028	294,441	11,288,221											
Loss for the year	-	-	-	-	-	(317,429)	-	(20,308)	(337,737)											
Fair value loss on biological assets	-	-	-	-	(3,232)	3,232	-	-	-											
Other comprehensive income	-	-	2,115,247	16,268	-	-	-	66,362	2,197,877											
Dividend paid to minority interest	-	-	-	-	-	-	-	(35,250)	(35,250)											
2nd Interim dividend for 2018 paid	-	-	-	-	-	-	-	(114,028)	(114,028)											
First Interim dividend for 2019 paid	-	-	-	-	-	-	-	(114,028)	(114,028)											
At 30 September 2019	228,055	96,530	9,742,812	50,839	195,370	2,264,204	-	305,245	12,885,055											
COMPANY STATEMENT OF CHANGES IN EQUITY																				
	Share Capital Kes '000	Capital Reserves Kes '000	Revaluation Reserves Kes '000	Defined Benefit Reserves Kes '000	Biological Assets Fair Value Kes '000	Retained Earnings Kes '000	Proposed Dividends Kes '000	Non Controlling Interest Kes '000	Total Kes '000											
At 1 October 2017	228,055	40,594	5,517,443	4,340	94,073	1,008,786	171,042	-	7,064,333											
Profit for the year	-	-	-	-	-	417,625	-	-	417,625											
Fair value loss on biological assets	-	-	-	-	24,323	(24,323)	-	-	-											
Other comprehensive income	-	-	-	909	-	-	-	909	909											
Final 2017 dividend paid	-	-	-	-	-	-	(171,042)	-	(171,042)											
First Interim 2018 dividend Paid	-	-	-	-	-	(114,028)	-	-	(114,028)											
Second Interim 2018 dividend payable	-	-	-	-	-	(114,028)	-	-	(114,028)											
At 30 September 2018	228,055	40,594	5,517,443	5,249	118,396	1,174,032	114,028	-	7,197,797											
At 1 October 2018 as Originally presented	228,055	40,594	5,517,443	5,249	118,396	1,174,032	114,028	-	7,197,797											
Change in accounting policy	-	-	-	-	-	(33,244)	-	-	(33,244)											
Restated as at 1 October 2018	228,055	40,594	5,517,443	5,249	118,396	1,140,788	114,028	-	7,164,553											
Profit for the year	-	-	-	-	-	52,762	-	-	52,762											
Fair value loss on biological assets	-	-	-	-	(45,217)	45,217	-	-	-											
Other comprehensive income	-	-	1,529,028	465	-	-	-	1,529,493	1,529,493											
Final 2018 dividend paid	-	-	-	-	-	-	(114,028)	-	(114,028)											
Interim dividend for 2019 paid	-	-	-	-	-	-	(114,028)	-	(114,028)											
At 30 September 2019	228,055	40,594	7,046,471	5,714	73,179	1,124,738	-	-	8,518,752											
COMMENTS ON THE AUDITED RESULTS FOR THE YEAR ENDED 30 SEPTEMBER 2019																				
Our expectation for the year's performance was severely affected by the significant dip in the tea and coffee prices experienced during the year. This was further compounded by severe weather conditions, high cost of production manifested in labour and input costs and lower production volumes especially in tea. The prices were lower than the cost of production throughout the financial year, leading to the absorption of cash reserves to support the continuation of the business. Despite these challenges, the diversification strategy is on course and the new lines of business are active and are expected to improve performance in the next year.																				
Tea production during the year declined by 14% to 9,318 tonnes of made tea down from 10,804 tonnes achieved in the previous year. The coffee estates produce went through a challenging period following prolonged extreme cold weather in prior year coupled with a dry period in the second quarter, which affected quality and size of the coffee beans and price. Coffee production however, was higher at 986 tonnes exceeding 891 tonnes produced in the previous year. Generally, global coffee and tea prices dipped to their lowest in over 10 years.																				
The avocado business maintained a steady and profitable performance during the second year of full operation despite effects of a poor crop and harvest due to the failed rains in the year.																				
During the year, we launched the macadamia commercial processing and trading activities having completed the capital investments of the factory in late 2018. The business however only started trading in the last quarter of the financial year and there are indications that going forward, this business unit is poised to be a central part and key contributor to our operations and profits.																				
The Group recorded a decline in turnover of 20% to Kes 2.8 billion compared to Kes 3.5 billion last year, the cost of sales declined by 11% to Kes 2.4 billion against prior year of Kes 2.7 billion and consequently a reduction in gross profit to Kes 434.7 million compared to Kes 852.1 million for the previous year.																				
The Group posted an overall loss after tax and non-controlling interest (including the changes in value of biological assets) of Kes 337.7 million (prior year Kes 233.5 million profit). This comprises of a loss from operating activities of Kes 314.2 million compared to a profit of Kes 256.6 million in the previous year for the group. The net loss from changes in the value of biological assets was KShs 3.2 million (prior year gain of KShs 38.9 million).																				
DIVIDEND An interim dividend of 50% (Kes 0.50 per share: 2018 – 50%; Kes 0.50 per share) was declared and paid on 16 July 2019. The directors do not recommend the payment of a final dividend (2018 – 50%; Kes 0.50 per share).																				
By Order of the Board																				
Dr. James Boyd McFie, PhD, FCPA Chairman					Mr. Martin R. Ochieng', MBA, Bsc Group Managing Director															
18th December, 2019					Certifications ISO 22000: 2005 Certified Rainforest Alliance Certification Flo Cert Certification C.A.F.E. Practices UTZ KAPEH Certification															
NOTICE IS HEREBY GIVEN THAT THE SIXTY-EIGHTH (68TH) ANNUAL GENERAL MEETING of the Company will be held at Kamundu Estate, Kiambu, on Friday, 6 March 2020 at 11.00 a.m. to conduct the following business:																				
Ordinary business																				
1. To table the proxies and note the presence of a quorum.																				
2. To read the Notice convening the meeting.																				
3. To consider and if approved, adopt the Company's audited financial statements for the year ended 30 September 2019, together with the Chairman's, Directors' and Auditors' Reports thereon.																				
4. To confirm the first interim dividend of 50% paid on 16 July 2019 to shareholders on the register of members as at close of business on 21 June 2019.																				
5. To approve payment of Directors' fees for the year ended 30 September 2019.																				
6. Auditors: To note that Messrs KPMG Kenya continue in office as Auditors by virtue of Section 721 (2) of the Companies Act, 2015 and to authorize the Directors to fix the Auditors' remuneration for the ensuing financial year.																				
7. To elect Directors:																				
(a) Dr Steve Omengie Mainda, who retires at this meeting in accordance with the provisions of Articles 94 and 95 of the Company's Articles of Association and Clause 2.5 of the Code of Corporate Governance Practices for Issuers of Securities to the Public 2015. Special notice is hereby given pursuant to Section 287 of the Companies Act, 2015, that notice has been received of the intention to propose the following Resolution as an Ordinary Resolution at the 2019 Annual General meeting: "That Dr Steve Omengie Mainda who has attained the age of 70 years, be and is hereby re-elected a Director of the Company until he comes up for retirement by rotation."																				
(b) Mr. Akif Butt, a Director retiring by rotation in accordance with Articles 94 and 95 of the Articles of Association of the Company and being eligible, offers himself for re-election.																				
8. In accordance with the provisions of Section 769 of the Companies Act, 2015, the following directors, being members of the Audit, Risk & Compliance Committee of the Board be elected to continue to serve as members of the said Committee:																				
(i) Mrs. Betty Koeh (ii) Mrs. Rosemary Muriyiri (iii) Mr. Sameer Merali (iv) Dr. James McFie																				
9. To consider any other business for which due notice has been given.																				
BY ORDER OF THE BOARD																				
LAWRENCE KIBET, CPS (K) COMPANY SECRETARY																				
Date: 18 December 2019																				